Roivant Sciences Ltd.

Roivant Sciences Ltd. has demonstrated strong stock performance, significantly outperforming the S&P 500 across various time frames. The company reported impressive returns over the past week, month, year, and three years, indicating a robust recovery and favorable market positioning within the Pharmaceuticals and Biotechnology sector.

Roivant Sciences has seen significant stock performance, with a notable increase today and impressive gains over the past month and year. Despite strong returns over various time frames, the company faces challenges, including declining net sales and a reduction in promoter confidence, indicating ongoing volatility in its financial landscape.

Roivant Sciences has achieved a new 52-week high, reflecting a substantial increase in its stock performance over the past year. As a mid-cap player in the Pharmaceuticals & Biotechnology sector, the company has a market capitalization of approximately USD 19.4 billion, despite currently operating at a loss.

Roivant Sciences achieved a new 52-week high of USD 29.20, reflecting a 170.89% increase over the past year. With a market capitalization of USD 19,431 million, the company faces financial challenges, including a negative return on equity and no dividend yield, as it focuses on growth and reinvestment.

Roivant Sciences has achieved a new 52-week high of USD 20.77, reflecting a substantial year-over-year performance increase. As a small-cap company in the Pharmaceuticals & Biotechnology sector, it has a market capitalization of USD 8,816 million and showcases notable resilience despite its loss-making status.

Roivant Sciences has achieved a new 52-week high, reflecting significant growth over the past year. The company, with a market capitalization of USD 8,816 million, has outperformed the S&P 500. However, it remains loss-making, with a negative return on equity and no dividend yield, emphasizing its growth-oriented strategy.

Roivant Sciences achieved a new 52-week high of USD 20.09 on October 31, 2025, reflecting an impressive one-year performance of 88.94%. With a market capitalization of USD 8,816 million, the company faces challenges, including a negative return on equity and a competitive industry landscape.

Roivant Sciences has achieved a new 52-week high, reflecting an impressive performance over the past year, significantly outpacing broader market growth. As a small-cap player in the Pharmaceuticals & Biotechnology sector, the company faces challenges, including a negative return on equity and a loss-making status, amidst its innovative strategies.

Roivant Sciences has achieved a new 52-week high of USD 17.12, reflecting a significant increase over the past year. The company, with a market capitalization of USD 8,816 million, operates in the Pharmaceuticals & Biotechnology sector and has experienced notable volatility, despite remaining in a loss-making position.

Roivant Sciences achieved a new 52-week high of USD 16.79 on October 6, 2025, reflecting a strong one-year performance of 53.69%. With a market capitalization of USD 8,816 million, the company operates in the Pharmaceuticals & Biotechnology sector, despite being loss-making and not offering dividends.

Roivant Sciences has achieved a new 52-week high of USD 16.19, reflecting a strong performance over the past year with a 52.84% increase. The company, with a market capitalization of USD 8,816 million, operates in the Pharmaceuticals & Biotechnology industry, despite facing financial challenges.

Roivant Sciences has achieved a new 52-week high of USD 16.14, significantly up from its low of USD 8.73, showcasing strong performance over the past year. With a market capitalization of USD 8,816 million, the company operates in the Pharmaceuticals & Biotechnology sector despite ongoing financial challenges.

Roivant Sciences saw a significant intraday increase on September 17, 2025, reaching USD 16.05. However, the company faces ongoing financial challenges, including declining net sales, a drastic drop in operating profit, and negative results for the past two quarters, raising concerns about its long-term growth prospects.

Roivant Sciences has achieved a new 52-week high of USD 16.05, reflecting a strong one-year performance of 44.42%. The company, with a market capitalization of USD 8,816 million, remains unprofitable and has a negative return on equity of -23.18%, while not offering dividends.